Tenax Therapeutics (NASDAQ:TENX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research report released on Friday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

TENX has been the subject of a number of other reports. William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. Leerink Partners set a $20.00 price objective on shares of Tenax Therapeutics in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Tenax Therapeutics Price Performance

NASDAQ TENX opened at $5.89 on Friday. The stock’s 50 day simple moving average is $5.86 and its 200-day simple moving average is $5.92. The company has a market cap of $24.43 million, a PE ratio of -2.38 and a beta of 1.92. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $7.89.

Tenax Therapeutics (NASDAQ:TENX) last posted its quarterly earnings data on Wednesday, May 14th. The specialty pharmaceutical company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.20. On average, equities research analysts anticipate that Tenax Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TENX. Two Sigma Investments LP purchased a new stake in shares of Tenax Therapeutics in the fourth quarter valued at about $84,000. Geode Capital Management LLC boosted its holdings in Tenax Therapeutics by 32.4% in the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after purchasing an additional 5,964 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of Tenax Therapeutics in the 4th quarter valued at approximately $166,000. ADAR1 Capital Management LLC increased its holdings in shares of Tenax Therapeutics by 98.1% during the 1st quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company’s stock worth $450,000 after buying an additional 34,048 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new stake in shares of Tenax Therapeutics during the 4th quarter worth approximately $1,026,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.